NeuroAiD is a natural product indicated for post-stroke recovery.
Following national regulations in each country, NeuroAiD is registered under various schemes, which includes dietary supplement, traditional medicine and herbal medicine. To date, NeuroAiD is available in over 30 countries worldwide and is constantly expanding its development
With promising clinical data on stroke recovery, with the support and involvement of international key opinion leaders in Neurology and experienced researchers, and with ongoing post-marketing experience, NeuroAiD aims to fill a worldwide medical need.
Prescription general Information
The recommended dosage is 2 capsules at a time, 3 times daily, for a minimum of 3 months.
Route of administration
Oral route with a glass of water. For people with difficulty to swallow, it is possible to open the capsules and to dilute the content in water. It is also possible to administer the diluted content via a gastric tube.
To date, no drug interactions with NeuroAiD have been reported. For more information on the Safety, click HERE.
Published clinical trials have confirmed that NeuroAiD has no blood thinning effect or effect on liver or renal functions. Similarly, NeuroAiD has neither any effect on blood pressure, and doesn’t induce any change in cardiac, hematological, hemostatic and biochemical parameters.1,2
Clinical trials on NeuroAiD reported only rare cases of nausea, minor headaches, increased thirst, dry mouth and vomiting for patients taking NeuroAiD. In these cases, patients should be advised to halve the dose of NeuroAiD during the first week and progressively increase it.
The use of NeuroAiD in pregnant and lactating women is not well established, and cannot be recommended. To date, no other contraindications are known.
1. Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases 2010;30:1-6.
2. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases 2008;25:450-456